SAINT LAURENT, Quebec, Aug. 26, 2013 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”) previously announced the submission to the U.S. Food and Drug Administration (“FDA”) of an Abbreviated New Drug Application (“ANDA”) filing for approval of a generic formulation of buprenorphine and naloxone Sublingual Film, which had been submitted by Par Pharmaceutical Companies, Inc., our commercialization partner for this product. The reference listed drug is Suboxone® (buprenorphine and naloxone) Sublingual Film.
Help employers find you! Check out all the jobs and post your resume.